| Literature DB >> 32649875 |
Yi-Ju Chen1, Theodoros I Roumeliotis2, Ya-Hsuan Chang3, Ching-Tai Chen4, Chia-Li Han5, Miao-Hsia Lin1, Huei-Wen Chen6, Gee-Chen Chang7, Yih-Leong Chang8, Chen-Tu Wu8, Mong-Wei Lin9, Min-Shu Hsieh8, Yu-Tai Wang10, Yet-Ran Chen11, Inge Jonassen12, Fatemeh Zamanzad Ghavidel12, Ze-Shiang Lin13, Kuen-Tyng Lin1, Ching-Wen Chen13, Pei-Yuan Sheu13, Chen-Ting Hung13, Ke-Chieh Huang1, Hao-Chin Yang1, Pei-Yi Lin1, Ta-Chi Yen1, Yi-Wei Lin9, Jen-Hung Wang4, Lovely Raghav14, Chien-Yu Lin3, Yan-Si Chen3, Pei-Shan Wu1, Chi-Ting Lai1, Shao-Hsing Weng1, Kang-Yi Su15, Wei-Hung Chang11, Pang-Yan Tsai11, Ana I Robles16, Henry Rodriguez16, Yi-Jing Hsiao13, Wen-Hsin Chang17, Ting-Yi Sung18, Jin-Shing Chen19, Sung-Liang Yu20, Jyoti S Choudhary21, Hsuan-Yu Chen22, Pan-Chyr Yang23, Yu-Ju Chen24.
Abstract
Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Mutational signature analysis revealed age- and gender-related mutagenesis mechanisms, characterized by high prevalence of APOBEC mutational signature in younger females and over-representation of environmental carcinogen-like mutational signatures in older females. A proteomics-informed classification distinguished the clinical characteristics of early stage patients with EGFR mutations. Furthermore, integrated protein network analysis revealed the cellular remodeling underpinning clinical trajectories and nominated candidate biomarkers for patient stratification and therapeutic intervention. This multi-omic molecular architecture may help develop strategies for management of early stage never-smoker lung adenocarcinoma.Entities:
Keywords: APOBEC signature; MMP; carcinogen signature; genomics; lung cancer; non-smoker; phosphoproteomics; proteogenomics; proteomics; subtyping
Mesh:
Substances:
Year: 2020 PMID: 32649875 DOI: 10.1016/j.cell.2020.06.012
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582